JP2008528678A5 - - Google Patents

Download PDF

Info

Publication number
JP2008528678A5
JP2008528678A5 JP2007553747A JP2007553747A JP2008528678A5 JP 2008528678 A5 JP2008528678 A5 JP 2008528678A5 JP 2007553747 A JP2007553747 A JP 2007553747A JP 2007553747 A JP2007553747 A JP 2007553747A JP 2008528678 A5 JP2008528678 A5 JP 2008528678A5
Authority
JP
Japan
Prior art keywords
formulation
connexin
subject
administered
vascular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2007553747A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008528678A (ja
JP5964538B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2006/001961 external-priority patent/WO2006134494A2/en
Publication of JP2008528678A publication Critical patent/JP2008528678A/ja
Publication of JP2008528678A5 publication Critical patent/JP2008528678A5/ja
Application granted granted Critical
Publication of JP5964538B2 publication Critical patent/JP5964538B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2007553747A 2005-02-03 2006-02-03 抗コネキシン化合物およびそれらの使用 Expired - Fee Related JP5964538B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65007505P 2005-02-03 2005-02-03
US60/650,075 2005-02-03
PCT/IB2006/001961 WO2006134494A2 (en) 2005-02-03 2006-02-03 Anti-connexin compounds and therapeutic uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012047133A Division JP2012107065A (ja) 2005-02-03 2012-03-02 抗コネキシン化合物およびそれらの使用

Publications (3)

Publication Number Publication Date
JP2008528678A JP2008528678A (ja) 2008-07-31
JP2008528678A5 true JP2008528678A5 (https=) 2009-03-12
JP5964538B2 JP5964538B2 (ja) 2016-08-03

Family

ID=37532679

Family Applications (6)

Application Number Title Priority Date Filing Date
JP2007553747A Expired - Fee Related JP5964538B2 (ja) 2005-02-03 2006-02-03 抗コネキシン化合物およびそれらの使用
JP2012047133A Withdrawn JP2012107065A (ja) 2005-02-03 2012-03-02 抗コネキシン化合物およびそれらの使用
JP2014121150A Withdrawn JP2014169325A (ja) 2005-02-03 2014-06-12 抗コネキシン化合物およびそれらの使用
JP2016159323A Withdrawn JP2016193942A (ja) 2005-02-03 2016-08-15 抗コネキシン化合物およびそれらの使用
JP2018077563A Pending JP2018111724A (ja) 2005-02-03 2018-04-13 抗コネキシン化合物およびそれらの使用
JP2019149110A Withdrawn JP2019194268A (ja) 2005-02-03 2019-08-15 抗コネキシン化合物およびそれらの使用

Family Applications After (5)

Application Number Title Priority Date Filing Date
JP2012047133A Withdrawn JP2012107065A (ja) 2005-02-03 2012-03-02 抗コネキシン化合物およびそれらの使用
JP2014121150A Withdrawn JP2014169325A (ja) 2005-02-03 2014-06-12 抗コネキシン化合物およびそれらの使用
JP2016159323A Withdrawn JP2016193942A (ja) 2005-02-03 2016-08-15 抗コネキシン化合物およびそれらの使用
JP2018077563A Pending JP2018111724A (ja) 2005-02-03 2018-04-13 抗コネキシン化合物およびそれらの使用
JP2019149110A Withdrawn JP2019194268A (ja) 2005-02-03 2019-08-15 抗コネキシン化合物およびそれらの使用

Country Status (12)

Country Link
US (2) US9248141B2 (https=)
EP (5) EP2510937A1 (https=)
JP (6) JP5964538B2 (https=)
KR (4) KR101840445B1 (https=)
CN (2) CN101573131B (https=)
AU (2) AU2006257283A1 (https=)
CA (1) CA2596412A1 (https=)
DK (1) DK1959981T3 (https=)
ES (1) ES2766549T3 (https=)
HK (1) HK1258903A1 (https=)
HU (1) HUE047335T2 (https=)
WO (1) WO2006134494A2 (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
SG158153A1 (en) 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
AU2014204482B2 (en) * 2006-12-11 2016-07-07 Coda Therapeutics, Inc. Anticonnexin polynucleotides as impaired wound healing compositions
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
DK2166845T3 (en) * 2007-06-21 2016-02-01 Musc Found For Res Dev ALFA-connexin C-terminal (ACT) peptides FOR THE TREATMENT OF AGE-related macular degeneration
NZ583803A (en) 2007-09-07 2012-12-21 Ind Res Ltd Agents with angiogenic and wound healing activity
EP2245158A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110300130A1 (en) * 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
US20110144182A1 (en) * 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
JP2011507861A (ja) * 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
JP2011507599A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
CA2710375A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
US20110243964A1 (en) * 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
AU2008343839A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
TW200950824A (en) 2008-04-30 2009-12-16 Kci Licensing Inc Use of nucleic acids with reduced pressure therapy
WO2009148552A2 (en) * 2008-06-02 2009-12-10 Kansas State University Research Foundation Methods and compositions for treating disease
US20110223204A1 (en) * 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds
ITCH20080021A1 (it) * 2008-09-25 2010-03-26 Saverio Alberti Usi in diagnosi e terapia dei tumori di un rna di fusione tra ciclina d1 e trop2
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
CA2866115C (en) 2012-03-01 2020-03-24 Firststring Research, Inc. Topical gels containing alpha connexin c-terminal (act) peptides
US9345744B2 (en) 2012-04-25 2016-05-24 Musc Foundation For Research Development Peptide-based collagen modulators for wound healing and tissue repair
WO2013168642A1 (ja) 2012-05-08 2013-11-14 石原産業株式会社 置換安息香酸化合物の製造方法
WO2013179264A2 (en) 2012-05-30 2013-12-05 Universidad Andres Bello Use of compounds that selectively modulate astrocytic release of substances through hemichannels of connexins and pannexins, without influencing gap junctions, for the treatment of psychiatric disorders
US9156896B2 (en) 2013-03-15 2015-10-13 Coda Therapeutics, Inc. Wound healing compositions and treatments
CA2921652A1 (en) 2013-08-21 2015-02-26 Manuel A. Riquelme Compositions and methods for targeting connexin hemichannels
WO2015191795A1 (en) * 2014-06-12 2015-12-17 The Research Foundation For The State University Of New York Methods of using gap junctions as therapeutic targets for the treatment of degenerative disorders of the retina
US10465188B2 (en) 2014-08-22 2019-11-05 Auckland Uniservices Limited Channel modulators
JP7185655B2 (ja) * 2014-08-22 2022-12-07 オークランド ユニサービシーズ リミティド チャネル調節剤
JP6898848B2 (ja) 2014-09-19 2021-07-07 メモリアル スローン ケタリング キャンサー センター 脳転移を治療するための方法
CN108024976A (zh) 2015-07-15 2018-05-11 特兰埃克斯公司 阿米替林用于阻断大脑半通道的用途和用于增强其体内作用的方法
EP3331545B1 (en) * 2015-08-06 2021-03-10 The Feinstein Institute for Medical Research Hemichannel extracellular-domain specific agents for treating sepsis
CA3033909A1 (en) * 2015-08-14 2017-02-23 The University Of Sydney Connexin 45 inhibition for therapy
CN105566495B (zh) * 2016-01-27 2019-10-22 上海科技大学 一种特异性抑制连接蛋白26的全人抗体
EP3419998A4 (en) 2016-02-26 2019-09-25 The Board of Regents of The University of Texas System CONNEXIN (CX) 43 HEMICANAL BINDING ANTIBODIES AND USES THEREOF
US11433116B2 (en) * 2016-04-14 2022-09-06 Cedars-Sinai Medical Center GJA1 isoforms protect against metabolic stress
CA3022763A1 (en) * 2016-05-03 2017-11-09 University Of Auckland Novel peptides and peptidomimetics
US11136368B2 (en) 2016-08-23 2021-10-05 The Cleveland Clinic Foundation Cancer treatment using CX26 blocking peptides
EP3521377A4 (en) 2016-09-30 2019-10-02 FUJIFILM Corporation AQUEOUS SOLUTION, COLOR COMPOSITION, INK IRRIGATION INK INK, INK IRRIGATION METHOD AND INK CARTRIDGE
CN111201247A (zh) 2017-04-28 2020-05-26 奥克兰联合服务有限公司 治疗方法和新颖构建体
CA3070089A1 (en) 2017-07-19 2019-01-24 Auckland Uniservices Limited Cytokine modulation
ES2976559T3 (es) * 2017-09-20 2024-08-05 Univ California Terapia génica con conexina 43 para restaurar la función eléctrica y cardíaca y la estructura cardíaca, en la miocardiopatía arritmogénica del ventrículo derecho
US12098385B2 (en) 2017-09-20 2024-09-24 The Regents Of The University Of California Gene therapy strategy to restore cardiac electrical and structural function in arrhythmogenic right ventricular cardiomyopathy
CN107469071B (zh) * 2017-09-29 2021-01-26 河南大学 Connexin模拟肽在制备预防或治疗急性肺损伤药物中的应用
CN108066744A (zh) * 2017-12-29 2018-05-25 于海龙 细胞连接蛋白43模拟肽Gap19在制备治疗脑出血药物中的用途
US12227561B2 (en) 2018-04-02 2025-02-18 Alamab Therapeutics, Inc. Connexin 43 antibodies and use thereof
CN108588075A (zh) * 2018-05-03 2018-09-28 天德悦（北京）生物科技有限责任公司 人Cx43基因干扰序列、shRNA-Cx43病毒及低表达Cx43蛋白的细胞系
WO2019222800A1 (en) * 2018-05-21 2019-11-28 Hudson Institute of Medical Research Methods for the treatment or prevention of autoimmune or autoinflammatory diseases
IL285369B2 (en) * 2019-02-04 2025-10-01 Alamab Therapeutics Inc Connexin 43 antibodies and their use
CN111484981B (zh) * 2020-04-26 2021-02-02 四川省人民医院 一种用于构建视网膜新生血管疾病模型的方法和应用
JP7036158B2 (ja) * 2020-07-08 2022-03-15 株式会社リコー 表示画像作成装置および画像表示装置
JP2023537316A (ja) 2020-07-31 2023-08-31 アラマブ セラピューティクス， インコーポレイテッド 抗コネキシン抗体製剤
JP2023546757A (ja) 2020-10-22 2023-11-07 シークエル・バイオ・インコーポレイテッド ペプチド製剤および眼科におけるその使用
CN114859057A (zh) * 2022-04-13 2022-08-05 江苏省中医院 人结直肠癌或人结直肠癌转移的预测性生物标志物及其应用
US20240327488A1 (en) 2023-03-28 2024-10-03 Universidad Del Desarrollo Connexin-46 peptide modulator
US20250059264A1 (en) * 2023-08-14 2025-02-20 Alamab Therapeutics, Inc. Method of treating stroke

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3687808A (en) 1969-08-14 1972-08-29 Univ Leland Stanford Junior Synthetic polynucleotides
US5034506A (en) 1985-03-15 1991-07-23 Anti-Gene Development Group Uncharged morpholino-based polymers having achiral intersubunit linkages
US4861757A (en) 1986-11-14 1989-08-29 Institute Of Molecular Biology Wound healing and bone regeneration using PDGF and IGF-I
JPH0539594Y2 (https=) 1988-08-05 1993-10-07
US5004810A (en) 1988-09-30 1991-04-02 Schering Corporation Antiviral oligomers
US5166195A (en) 1990-05-11 1992-11-24 Isis Pharmaceuticals, Inc. Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides
FR2692265B1 (fr) 1992-05-25 1996-11-08 Centre Nat Rech Scient Composes biologiquement actifs de type phosphotriesters.
GB2273932A (en) 1992-11-24 1994-07-06 Stiefel Laboratories Stable oligonucleotides
GB9425930D0 (en) 1994-12-22 1995-02-22 Procter & Gamble Silicone compositions
US20030148968A1 (en) 1995-02-28 2003-08-07 Hammond H. Kirk Techniques and compositions for treating cardiovascular disease by in vivo gene delivery
US6752987B1 (en) 1995-02-28 2004-06-22 The Regents Of The University Of California Adenovirus encoding human adenylylcyclase (AC) VI
JP2001505432A (ja) 1996-12-02 2001-04-24 ダイヤド ファーマシューティカル コーポレイション ヒト接着分子のアンチセンス阻害
AU9016898A (en) 1997-08-07 1999-03-01 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Methods and compositions for treatment of restenosis
EP1037981A1 (en) 1997-12-09 2000-09-27 Children's Medical Center Corporation Soluble inhibitors of vascular endothelial growth factor and use thereof
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
DK1146908T3 (da) * 1999-01-27 2005-10-10 Becker David Dr Formuleringer omfattende antisense-nukleotider mod connexiner
US5998148A (en) 1999-04-08 1999-12-07 Isis Pharmaceuticals Inc. Antisense modulation of microtubule-associated protein 4 expression
EP2298333A3 (en) * 1999-12-20 2012-05-02 Immunex Corporation Tweak receptor
JP2004531461A (ja) 2000-10-18 2004-10-14 チルドレンズ メディカル センター コーポレーション オステオポンチン被覆表面および使用方法
RU2420537C2 (ru) 2001-01-17 2011-06-10 Трабьон Фармасьютикалз Инк. Слитые белки связывающий домен-иммуноглобулин
US20050119211A1 (en) 2001-05-18 2005-06-02 Sirna Therapeutics, Inc. RNA mediated inhibition connexin gene expression using short interfering nucleic acid (siNA)
WO2003032964A2 (en) * 2001-10-17 2003-04-24 University Of Wales College Of Medecine Gap junctions and endothelial-derived hyperpolarizing factor (edhf)
HRP20040784A2 (en) 2002-01-29 2005-04-30 Wyeth Compositions and methods for modulating connexin hemichannels
JP2003238441A (ja) * 2002-02-08 2003-08-27 英行 ▲高▼野 血管新生抑制剤
WO2003096981A2 (en) 2002-05-15 2003-11-27 Seul, Kyung, Hwan Method of modulating angiogenesis
JP2004073182A (ja) * 2002-05-24 2004-03-11 Takeda Chem Ind Ltd インスリン抵抗性改善剤
US8809504B2 (en) 2002-09-03 2014-08-19 Vit Lauermann Inhibitor which is deactivatable by a reagent produced by a target cell
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
PT1606318E (pt) * 2003-03-26 2009-11-10 Deutsches Krebsforsch Proteínas de fusão de fc melhoradas
EP1514929A1 (en) 2003-09-12 2005-03-16 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Antisense oligonucleotides for prevention of metastasis formation of cancer cells
CA3059497A1 (en) 2003-12-03 2005-06-16 Ocunexus Therapeutics, Inc. Antisense compounds targeted to connexins and methods of use thereof
DE102004027422A1 (de) 2004-06-04 2005-12-29 Boehringer Ingelheim Microparts Gmbh Vorrichtung zur Aufnahme von Blut und Abtrennung von Blutbestandteilen
SG158153A1 (en) * 2004-12-21 2010-01-29 Musc Found For Res Dev Compositions and methods for promoting wound healing and tissue regeneration
DK1959981T3 (da) 2005-02-03 2020-01-27 Coda Therapeutics Ltd Anti-connexin 43 forbindelser til behandling af kroniske sår
EA200870058A1 (ru) 2005-12-16 2008-12-30 Арла Фудс Амба Композиции, содержащие остеопонтин крупного рогатого скота, для улучшения процесса заживления ран
EP2091557A2 (en) 2006-11-15 2009-08-26 Coda Therapeutics, INC. Improved methods and compositions for wound healing
CN101835476B (zh) 2006-12-11 2016-08-17 科达治疗公司 作为受损伤口愈合组合物的抗连接蛋白多核苷酸
EP2114422A1 (en) 2007-03-02 2009-11-11 National University of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
CN101765423B (zh) 2007-05-31 2014-08-06 安特里奥公司 核酸纳米粒子和其用途
EP2245158A2 (en) 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20110300130A1 (en) 2007-12-11 2011-12-08 Becker David L Impaired wound healing compositions and treatments
CA2710375A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of orthopedic conditions
CA2710232A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Treatment of abnormal or excessive scars
US20110144182A1 (en) 2007-12-21 2011-06-16 David Lawrence Becker Treatment of surgical adhesions
US20110243964A1 (en) 2007-12-21 2011-10-06 Bradford James Duft Treatment of orthopedic conditions
US8975237B2 (en) 2007-12-21 2015-03-10 Coda Therapeutics, Inc. Treatment of fibrotic conditions
AU2008343758A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin 43 polynucleotides for the treatment of abnormal or excessive scars
AU2008343839A1 (en) 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin peptides, alone or in combination with anti-connexin polynucleotides, for the treatment of surgical adhesions
JP2011507599A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 改良医療デバイス
JP2011507861A (ja) 2007-12-21 2011-03-10 コーダ セラピューティクス， インコーポレイテッド 線維症性の状態の治療のための抗コネキシンポリヌクレオチド剤と組み合わせた抗コネキシンポリペプチド剤の使用
US20110038920A1 (en) 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
US20110223204A1 (en) 2008-06-04 2011-09-15 Bradford J Duft Treatment of pain with gap junction modulation compounds

Similar Documents

Publication Publication Date Title
JP2008528678A5 (https=)
ES2766549T3 (es) Compuestos anticonexina 43 para el tratamiento de heridas crónicas
US20250270555A1 (en) Organic compositions to treat beta-catenin-related diseases
JP4913072B2 (ja) 椎間板の疾患を治療、阻害及び回復するための方法及び組成物
US20120277144A1 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
CN118955715A (zh) Alk2抗体及其使用方法
JP2012528597A (ja) 血小板グリコプロテインｖｉの核酸調節因子
Wang et al. Transplantation of EPCs overexpressing PDGFR-β promotes vascular repair in the early phase after vascular injury
US20110123534A1 (en) Novel compounds for modulating neovascularisation and methods of treatment using these compounds
RU2682675C2 (ru) Композиция для применения при лечении боли, связанной с межпозвоночным диском
CN116615540B (zh) 用于调节血管紧张素原表达的化合物和方法
JP7360170B2 (ja) 虚血病変部位特異的な遺伝子治療法
US12540330B2 (en) Stem-loop compositions and methods for inhibiting vascular endothelial growth factor
US20250326799A1 (en) Agents inducing vascularisation
CN121249673B (zh) 一种靶向ybx1的骨关节炎治疗与诊断产品及应用
KR101190200B1 (ko) Ｍｓｘ1 단백질 또는 이를 코딩하는 유전자를 포함하는 혈관내피세포의 혈관신생 저해제
KR100909867B1 (ko) 골대사성 질환의 예방 및 치료를 위한 조성물
WO2005034978A2 (en) MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF
WO2017210671A1 (en) Methods and compositions for treating heart failure
CA3226001A1 (en) Oligonucleotide for inhibiting quaking activity
CN120643672A (zh) Zyxin蛋白在制备高血压所致肾间质纤维化的产品中的应用
WO2015045333A1 (ja) 心筋細胞増殖誘導剤及びこれを含有する医薬組成物、並びに心筋細胞の製造方法
Jeong et al. COMP-angiopoietin-1 stimulates synovial proliferation but suppresses osteoclast by enhancing angiogenesis and osteoblast maturation in collagen-induced arthritis
Sebastian Grundmann et al. A NEW INTRA-ARTERIAL DELIVERY PLATFORM FOR PRO-ARTERIOGENIC COMPOUNDS TO STIMULATE COLLATERAL ARTERY GROWTH VIA TRANSFORMING GROWTH FACTOR BETA1 RELEASE
Kempf et al. Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction